Form 4: Celularity Director Diane Parks Receives Equity Grants

Celularity Inc. Director Diane L. Parks was granted 125,000 restricted stock units and 156,250 stock options under the company's 2021 Equity Incentive Plan.

Summary

• Diane L. Parks, a Director of Celularity Inc., received equity grants on December 29, 2025.
• The grants include 125,000 Restricted Stock Units (RSUs) for Class A Common Stock, with a grant price of $0.00.
• The grants also include 156,250 stock options for Class A Common Stock, with an exercise price of $1.20 and a grant price of $0.00.
• The stock options have an expiration date of December 29, 2035.
• Both the RSUs and stock options were granted under the Celularity Inc. 2021 Equity Incentive Plan.
• The RSUs and options will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, contingent on Ms. Parks' continuous service.
• Following these transactions, Ms. Parks beneficially owns 490,021 Class A Common Stock (including the 125,000 RSUs) and 518,774 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is generally a neutral to slightly positive event as it aligns interests. It does not contain information that would significantly alter the company's fundamental outlook or financial performance in the short term.

Positives

• The grants align the director's interests with shareholders, incentivizing long-term performance.
• The equity incentive plan is a standard mechanism for attracting and retaining key personnel.

Future Outlook

The granted Restricted Stock Units and stock options are subject to vesting conditions, becoming exercisable on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, provided continuous service with the Issuer is maintained.

Industry Context

Equity grants to directors are a common practice across industries, particularly in biotechnology and growth-oriented companies like Celularity, to incentivize long-term commitment and align leadership interests with shareholder value creation. The use of a 2021 Equity Incentive Plan suggests a structured approach to compensation.

Comparison to Industry Standards

• Equity compensation for directors, including RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical sectors.
• Companies such as Moderna, BioNTech, and Regeneron frequently utilize similar incentive plans to attract and retain top talent and board members.
• The vesting schedule tied to continuous service and annual meetings is also typical, ensuring ongoing commitment.
• The specific number of units and options granted would need to be benchmarked against peer companies of similar market capitalization and stage of development to assess if it's within industry norms, but the mechanism itself is standard.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders, potentially leading to better long-term decision-making. However, future exercise of options or vesting of RSUs could lead to minor dilution.
• Employees: No direct impact on general employees mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The RSUs and stock options will vest on the earlier of December 29, 2026 (one-year anniversary) or the date of the next annual stockholder meeting, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice aimed at aligning management and director interests with shareholder value. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions while awaiting more substantive corporate updates.

Keywords

Celularity Inc., CELU, Diane L. Parks, Form 4, SEC filing, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Director compensation, Insider transaction